Sphera Funds Management’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
Other funds holding ACAD
BBA
Sphera Funds Management's ACAD Position: Q3 2026 in Review
Sphera Funds Management reduced its Acadia Pharmaceuticals (ACAD) stake by 43% in Q3 2026, selling an estimated $4.15M and leaving 202,087 shares worth $4.07M. The position accounts for 0.58% of the portfolio, ranked #56.
Sphera Funds Management first reported a position in ACAD in Q4 2013 and has held it in 18 quarters since. The position peaked at $15.3M in Q4 2019. 350 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.
- Sphera Funds Management held 202,087 shares of Acadia Pharmaceuticals worth $4.07M as of Q3 2026.
- Sphera Funds Management sold 154,447 Acadia Pharmaceuticals shares in Q3 2026, an estimated $4.15M.
- Acadia Pharmaceuticals made up 0.58% of Sphera Funds Management's portfolio in Q3 2026, its #56 holding.
- Sphera Funds Management first reported a position in Acadia Pharmaceuticals in Q4 2013 and has held it in 18 quarters since.
- Sphera Funds Management's Acadia Pharmaceuticals position peaked at $15.3M in Q4 2019.
- 350 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.
Based on Sphera Funds Management's 13F filing for Q3 2026, filed 16 Nov 2026.